ESLA — Estrella Immunopharma Income Statement
0.000.00%
Last trade - 00:00- $41.97m
- $40.17m
Annual income statement for Estrella Immunopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Total Operating Expenses | 1.69 | 11.1 | 7.31 |
| Operating Profit | -1.69 | -11.1 | -7.31 |
| Net Income Before Taxes | -1.69 | -11.1 | -7.31 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -1.69 | -11.1 | -7.31 |
| Net Income Before Extraordinary Items | |||
| Net Income | -1.69 | -11.1 | -7.31 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -1.69 | -11.1 | -7.31 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.048 | -0.316 | -0.201 |